



# **Neurodegeneration and Remyelination in MS**

- **Axon loss**
- **Neurodegeneration**
- **Atrophy**
- **Incidence of remyelination in MS**
- **Mechanisms of remyelination**



# Multiple Sclerosis is an inflammatory demyelinating disease of the CNS



It is now thought that axonal loss is the major pathological correlate of the progressive irreversible neurological deficit in chronic MS





## Axon Loss in Multiple Sclerosis



• early studies noted axon damage and their relative but not absolute preservation.

- axonal loss is present in all MS lesions, ranging from 20% to nearly 100% loss
- 65% loss in cervical cord lesions of SP MS
- larger axons better preserved than smaller ones


## Axonal damage in MS




[Kuhlmann et al \(2002\)](#)

- axon loss occurs during early inflammatory attacks and continues throughout the course of MS
- extensive axon and neurite damage and neuronal loss seen in grey matter MS lesions
- not much evidence of direct immune attack to date

## Spinal cord axon loss in MS



Control




MS

# Axon degeneration in MS

- Direct or bystander immune-mediated attack...TNFa or Fas ligand
- Energy deficiency: inherent mitochondrial defects or due to damage by inflammatory milieu (e.g free radicals)
- Glutamate excitotoxicity
- Antibodies to neurofascin, a component of the node/paranode (Mathy et al, 2007)
- **Na<sup>+</sup> and Ca<sup>2+</sup> overloading in electrically active/ energy depleted axons** (Trapp and Stys, 2009)
- Detected indirectly in patients by MRS for N-acetyl-aspartate (NAA). Reduction in NAA level correlates with increasing disability.

# Neurodegeneration leads to chronic progression



**Inflammatory cells release free radicals and cytotoxic mediators**




**A build up of damage kills the neuron**

**This is irreversible but there is spare capacity**

**Neuroprotective treatments should stop progression**





### Chronically demyelinated axons degenerate due to ionic imbalance and calcium influx

(A) In normal myelinated axons, action potentials are propagated through the opening of Na<sup>+</sup> channels at the node. Na<sup>+</sup> also enters through Na<sup>+</sup>/Ca<sup>2+</sup> exchangers, which passively trade Na<sup>+</sup> entry for Ca<sup>2+</sup> removal. Na<sup>+</sup> entry is rebalanced by removal through internodal Na<sup>+</sup>/K<sup>+</sup> ATPase, which uses ATP produced by axonal mitochondria to pump Na<sup>+</sup> out in exchange for K<sup>+</sup>.

(B) Na<sup>+</sup> channels are diffusively distributed along demyelinated axons resulting in increased Na<sup>+</sup> influx during impulse transmission and increased ATP demand for operating Na<sup>+</sup>/K<sup>+</sup> ATPase pumps.

(C) Alterations in ATP production reduce Na<sup>+</sup>/K<sup>+</sup> exchange capacity and increase axonal accumulation of Na<sup>+</sup>.

(D) Increased axonal Na<sup>+</sup> reverses the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger, and increases axonal Ca<sup>2+</sup>.

(E) Increased Ca<sup>2+</sup> activates proteolytic enzymes, leading to damage of axoplasmic contents (F) and eventually to axonal death.




**Does axonal loss resulting from  
inflammation/demyelination produce clinical progression  
in models of MS ?**

# MOG-EAE in the DA rat





## Induction of EAE

- Adult female DA rats.
- Recombinant mouse MOG (100 $\mu$ g) N terminal extracellular domain (1-116a.a.) in IFA.
- Single SC injection in the dorsal aspect of the base of the tail.




## Disease courses



# Inflammation & demyelination in MOG-EAE




## Neuronal/axonal damage and loss in MOG-induced EAE




- In addition to inflammation and demyelination, injection of DA rats with recombinant MOG also results in neuronal and axonal changes in the spinal cord.
- Disorganisation of axonal fascicles and reduction in axonal density is seen in areas of demyelination (A).
- MBP/Neurofilament double immunostaining reveals areas of Wallerian degeneration (B) and axonal dystrophy (C).

## Neuronal and axonal changes in MOG-EAE




Swollen and degenerating axons (granular disintegration of cytoskeleton) are frequently seen in areas of inflammation and demyelination




Degenerative changes to spinal motoneurons are seen in areas of inflammation in the grey matter and close to white matter lesions. Loss of motoneurons is seen at some levels.


# Methodology for Quantification of Spinal Cord Pathology




Toluidine blue stained semi thin sections



OX-42 immunohistochemistry




## Axonal loss occurs early after disease onset with small axons most affected







# Demyelination, Inflammation & Axon loss determine disability in progressive EAE



OX-42 cell density correlates significantly with disease severity in progressive EAE ( $r=0.695$ ,  $p<0.01$ ).







Demyelination correlates significantly with disease severity ( $r = 0.676$ ,  $p<0.01$ ).



Axon loss correlates significantly with disease severity in progressive EAE ( $r=0.69$ ,  $p<0.01$ ).

Fibre loss is episodic in relapsing EAE corresponding to the number of relapses and correlates with disability.




The percentage of axon loss correlates significantly with the number of relapses ( $r$  Pearson=0.89,  $p < 0.001$ )

In relapsing EAE, axon loss exhibits a significant correlation with disease severity ( $r = 0.90$ ,  $p < 0.01$ ).


## AXON LOSS - CONCLUSIONS

1. There is significant axonal loss (~ 44-65% total), which is comparable to the numbers reported by neuropathological studies of axonal loss in MS spinal cord and may account for the accumulating disability observed in the model.
2. Significant loss of axons occurs early in the disease process but the exact mechanism remains to be elucidated
3. Small caliber fibres are more vulnerable to the pathogenetic mechanisms of MOG-induced EAE which is consistent with what has been observed in MS lesions.
4. Only axon loss correlates with increasing chronic clinical disability in relapsing-remitting MOG-EAE
5. May occur via mitochondrial insufficiency, ATP reduction, increased Na<sup>+</sup> loading, reversal of Na/K ATPase & subsequent calcium loading of axons (Trapp & Stys, 2009)



# Evidence for neurodegeneration in MS



- 20-30% of total cortical grey matter is demyelinated in SPMS and PPMS
- damage to axons and dendrites in grey matter lesions (*Peterson et al Ann Neurol 2001*)




- cell loss in grey matter lesions
- degenerating neurons in grey matter lesions
- neuronal loss in cerebral cortex
- 35% reduction in total neuronal numbers in mediodorsal thalamus



# Gray Matter Atrophy Is Related to Long-Term Disability in Multiple Sclerosis


Leonora K. Fisniku, MRCP,<sup>1,2</sup> Declan T. Chard, PhD,<sup>1,2</sup> Jonathan S. Jackson, MSci,<sup>1,2</sup>  
Valerie M. Anderson, BSci,<sup>1,2</sup> Daniel R. Altmann, PhD,<sup>1,3</sup> Katherine A. Miszkiel, MRCP,<sup>4</sup>  
Alan J. Thompson, PhD,<sup>1,5</sup> and David H. Miller, MD<sup>1,2</sup>

- there was significantly more GM, but not WM atrophy, in secondary-progressive MS versus relapsing-remitting MS ( $p$  0.003), and relapsing-remitting MS versus clinically isolated syndrome ( $p$  0.001).
- GM, but not WM, fraction correlated with expanded disability status scale ( $r_s$  0.48;  $p$  0.001) and MS Functional Composite scores ( $r_s$  0.59;  $p$  0.001).





Up to 20% reduction in cortical GM thickness

*Magliozzi et al, 2010*






## Axonal loss and neurodegeneration










## Neuronal changes in grey matter lesions





# MS grey matter pathology:




## Neuronal pathology in normal appearing grey matter







## Neuronal pathology in MS cases



Caspase 3 expressing neurons at the early stages of apoptosis are seen throughout the cortical GM in MS, but not in large numbers


# Cellular pathology of GM lesions

Precentral gyrus: motor cortex



Snap frozen tissue


(UK MS Tissue Bank)




10 F+SPMS { Ch A Type III GML  
NAGM

10 F-SPMS { Ch A Type III GML  
NAGM


10 Controls NAGM




adapted from Calvin & Ojemann 1994




NeuN + MAP2



GFAP



MHC-II + MBP




NogoA + CNP

# Decreased neuron density (NeuN+ nuclei)

## Clear evidence of a gradient of neuronal loss


C Percent reduction in NeuN+ neurons




Greatest neuronal density decrease in layer I & II of F+SPMS in GML (>60%) and NAGM (>50%)

40% reduction in layer 5 neurons

All the data for F+ cases are statistically significant ( $p < 0.0001$ ) compared to controls








Cells were co-labelled with NeuN/ smi32 and pyramidal neurons defined by shape, relative size, a primary dendrite extending towards pial surface as well as DAPI+ nucleus (n=10+10+10)


**65% loss of layer V pyramidal neurons in GMLs associated with B-cell follicles !!**

**Major consequences for motor function**


A fluorescence micrograph showing a dense network of neurons. The cytoplasm of the neurons is stained green, while their nuclei are stained blue. The neurons vary in size and shape, with some having long, thin processes extending from their cell bodies. The background is dark, making the green and blue signals stand out.

Over 50% loss of these large neurons in more rapidly progressing MS


**Neuron loss is greatest in those cases with an early age of death**



**Disease duration correlates with loss of pyramidal neurons**



**Reduction in pyramidal neuronal density correlates with time from wheelchair use to death**




B-cell follicle (B-cells, CD8+ T-cells, NK cells)



CHRONIC  
MICROGLIAL  
ACTIVATION



Types of Neurons in Cerebral Cortex





Damage to glia limitans


50% loss of pyramidal neurons

65% loss of pyramidal neurons

# Why are the neurons dying in MS ?




Which genes have been turned on and which have been turned off?





Do gene variations confer susceptibility to mild or aggressive disease?

24,000 genes  
(30,000)



Gene  
chip




282 up  
182 down

# Neuronal markers

Neurofilament H	2.2 fold down
Neurofilament M	2.1 fold down
Neurofilament L	1.5 fold down
Parvalbumin	3.7 fold down
GAD67	1.7 fold down
Presenilin	1.6 fold down
NRG1	2.0 fold down
FGF22	1.8 fold down
Synaptobrevin	2.7 fold down
Snap 25	1.7 fold down
Neuroigin 4	2.3 fold down
GABA-A $\alpha$ 1	1.6 fold down
NMDA 2A	1.6 fold down
AMPA 3	1.6 fold down
Na <sup>+</sup> v1 $\beta$	3.0 fold down
K <sup>+</sup> shaker 1	2.0 fold down
K <sup>+</sup> v KQT5	2.2 fold down
Ca <sup>2+</sup> v $\beta$ 4	1.7 fold down
Cl channel 4	1.7 fold down

Red arrows – aggressive MS  
Green arrows – milder MS

*Meninges*








# Relative quantity of IFN $\gamma$ and TNF mRNA in the meninges

(5 F+MS, 5 F-MS, 5 Ctrl)


## IFN $\gamma$



## TNF $\alpha$



CD3+IFN in the meninges of 2 F+MS




TNF in the meninges of 2 F+MS


# Relative quantity of TNFRs in the cortex

(6 F+MS, 6 F-MS, 6 Ctrl)

## TNF-R1A



## TNF-R1B




# Tumour Necrosis Factor (TNF)

+

## Interferon-gamma (IFN $\gamma$ )

### TNF-R1A

### TNF-R1B



# **Is multiple sclerosis a neurodegenerative disease ?**


- **Cortical pathology has a major impact on clinical progression in MS**
- **Presence of meningeal B-cell follicles leads to more extensive pathology and loss of neurons**
- **Cytotoxicity mediated by factors released by B-cells and/or CD8 T-cells and/or microglia**
- **How early during the disease course does this start?**
- **Different pathogenetic mechanisms may be involved in WM & GM pathology, suggesting novel treatment options**

**Multiple sclerosis is an inflammatory neurodegenerative disease**

**Does the brain try to repair  
the damage caused by  
MS ?**



# Demyelination in MS

## Oligodendrocytes in MS lesions



Oligodendrocytes are generally absent from the centre of chronic lesions although increased numbers are often seen at the lesion edge. MBP-expressing cells were found in large numbers at the edge of some MS lesions.

## Demyelination can be repaired



**REMYELINATION IS A NATURAL REPAIR  
PROCESS THAT SHOULD OCCUR IN MS**

***It can be stopped by ongoing  
inflammation and by accumulating  
damage to the axons***

**Remyelination restores conduction and protects axons**

## Remyelination in MS

- repair in MS is indicated by the presence of thinly remyelinated sheaths.
- remyelination is a frequent finding at the edge zones of inactive plaques.
- in the early stages of MS rapid and extensive remyelination may be the rule.
- complete remyelination of lesions can occur.
- Schwann cell remyelination is found in the spinal cord.
- if remyelination is effective during the early stages of MS why then does it fail as the disease progresses?



# Remyelination in MS

**A) WML with no repair**



LFB/CFV (X10)

**B) WML with partial repair**


LFB/CFV (X0.5)

**C) WML with complete repair**


LFB/CFV (X4)





# Myelin repair is a frequent finding in MS and may continue for a long time



MS42	MS58
51 yrs	51 yrs
20 yrs MS	21 yrs MS
<b>% REMYELINATION</b>	
<b>60%</b>	<b>35%</b>




The extent of remyelination of individual lesions is highly variable



**Fig. 3** Graph showing the statistically significant correlation between remyelination and disease duration (global sample;  $n = 39$ ;  $P = 0.021$ ;  $r = 0.374$ ).



## Oligodendrocytes in MS lesions

- **Recent studies of large series of autopsied and biopsied cases with few exceptions confirm that oligodendrocytes are largely lost in areas of active demyelination**
- **Oligodendrocytes frequently reappear in large numbers in recently demyelinated tissue**




- **Oligodendrocytes are present in only small numbers in chronic inactive lesions**

## Oligodendrocytes in MS lesions





MOG-expressing oligodendrocytes are found in MS lesions but are infrequent




## **Oligodendrocyte progenitors in MS lesions**

- **some progenitor cells are present in most chronic plaques, in the complete absence of remyelination**
- **progenitor numbers are highly variable**
- **progenitor numbers are highest in lesions which still contain macrophages**
- **virtually nothing is known about the fate of progenitors in the acute lesion**

# Oligodendrocyte progenitors in MS lesions



**Numbers of progenitors in chronic MS lesions are highly variable, from none to the same as the NAWM.**



## Myelin repair in MS


- remyelination leads to restoration of neurological function and may protect axons against damage
- *The adult mammalian brain and spinal cord has an enormous capacity for repairing myelin damage*




## Myelin repair in the mature CNS

- **Adult mammalian brain contains a widespread and numerous population of oligodendrocyte precursor cells.**
- **Glial progenitors in the adult CNS are cycling.**
- **When isolated into culture they differentiate into oligodendrocytes.**
- **Glial progenitor cells are thought to be responsible for oligodendrocyte replacement following demyelination. Evidence?**


## Distribution of glial progenitors in the adult rat



**Cerebral cortex**




**Hippocampus**




**Corpus callosum**

NG2-expressing glial progenitors are ubiquitously distributed throughout the adult mammalian CNS. Their morphology is varied according to their environment.

## Ratio of oligodendrocytes:microglia:progenitors




**NG2+ progenitors/oligodendrocytes**





**NG2+ progenitors/microglia**

## Ratio of oligodendrocytes:microglia:progenitors




- these ratios have significant implications for myelin repair
- in spinal cord progenitors will need to undergo at least 2 cell divisions to replace oligodendrocytes
- in cerebral cortex progenitors will only need to undergo 1 round of cell division

**NG2+ glial progenitors are the major cycling population of the mature CNS**



*NG2 - green, BrdU - red*





## Response of NG2<sup>+</sup> OPCs to demyelination in EAE




NG2<sup>+</sup> OPCs respond to demyelination with an increase in cell number, approximately 3 fold, irrespective of whether the demyelination occurred in the white matter or grey matter (C and D)

*Reynolds et al (2002) J Neurocytol 31:523-536*

# Remyelination of MOG-induced EAE lesions




# Mechanism for repair






# Mechanism for repair



# Mechanism for repair



## **When and why does remyelination fail in MS?**

- 1. Remyelination may not fail early on in MS and can be extensive at later stages**
- 2. The natural history of remyelination awaits good MRI measures**
- 3. Failure of remyelination is determined by the chronicity of individual lesions**
- 4. Reasons for failure of remyelination are many and may vary from patient to patient and from lesion to lesion**
- 5. It remains possible that preserving axon integrity may be sufficient to stimulate remyelination**

Kuhlmann et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. *Brain* 125:2202-2212.

Peterson et al (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical MS lesions. *Ann Neurol* 50:389-400.

Trapp & Stys, *Lancet Neurol* 2009.

Mathy et al (2007) Neurofascin as a novel target for autoantibody-mediated axonal injury. *J Exp Med* 204:2363-2372.

Papadopoulos et al (2006) Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. *Exp Neurol* 197:373-385.

Magliozzi et al (2010) A gradient of neuronal loss and meningeal inflammation in MS. *Ann Neurol* 68:477-493.

Patani et al (2007) Remyelination can be extensive in MS despite a long disease course. *Neuropath App Neurobiol* 33:277-287.

Patrikios et al (2006) Remyelination is extensive in a subset of multiple sclerosis patients. *Brain* 129:3165-3172

Dawson et al (2003) NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. *Mol Cell Neurosci* 24:476-488.

Reynolds et al (2002) The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. *J Neurocytol* 31:523-536

Franklin (2002) Why does remyelination fail in multiple sclerosis. *Nat Rev Neurosci* 3:1-10.

Polito & Reynolds (2005) NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult CNS. *J Anatomy* 207:707-716.